Recipharm AB, one of the leading contract pharmaceutical development and manufacturing organisations (CDMO), announces today its intention to acquire Cobra Biomanufacturing plc, a leading UK-based, cGMP compliant contract manufacturer of biopharmaceuticals. Move will more than double Recipharm’s biologics business.

The acquisition was made through a public offer of SEK232 in cash per share to the shareholders of Recipharm, and SEK1,504,295 in cash per convertible bond, totaling ~US$3 billion (SEK24.93 billion). Roar BidCo's shareholding in Recipharm now corresponds to approximately 95.1 per cent of the share capital and approximately 98.3 per cent of the

The acquisitions are expected to be accretive to EBITDA margin already from 2016 and are well in line with Recipharm’s overall financial objectives. “Recipharm has generated strong growth over the past years through a number of acquisitions, and today holds a strong position in the global CDMO market. EQT wants to support Recipharm’s continued development, which will require significant and long-term investments. Recipharm acquired inhaled commercial drug product manufacturing capacity in its deal with Sanofi, adding to its existing development capabilities in the area. Even so, the acquisition of Bespak will be a significant step up in its drug delivery device development and manufacturing capabilities, notably because it will add the capacity to make products such as auto-injectors. Setterwalls has assisted Recipharm AB (publ) in connection with an offer to acquire all shares in Consort Medical plc. The enlarged Recipharm Group is set to become a top five global CDMO (Contract Development and Manufacturing Organisation), able to offer integrated device development and supply combined with commercial scale finished dose manufacturing.

Recipharm acquisition

Recipharm Offers to Acquire Consort Medical to Become a Leading Inhalation Company and Top Five Global CDMO Player. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. Recipharm is a leading pharmaceutical contract development and manufacturing organisation (CDMO) headquartered in Stockholm with over 20 years’ experience. Private equity firm EQT AB agreed to buy Swedish pharmaceuticals company Recipharm AB for $2.1 billion, marking the latest in a wave of drug industry acquisitions. The acquisition was made through a public offer of SEK232 in cash per share to the shareholders of Recipharm, and SEK1,504,295 in cash per convertible bond, totaling ~US$3 billion (SEK24.93 billion). Roar BidCo's shareholding in Recipharm now corresponds to approximately 95.1 per cent of the share capital and approximately 98.3 per cent of the They have undertaken to contribute all of their shares in Recipharm to Roar BidCo in connection with completion of the Offer, entailing that Roar BidCo controls 21,312,000 shares of class A and 4,629,410 shares of class B, corresponding to 25.7 per cent of all outstanding shares and 74.3 per cent of the votes in Recipharm. Recipharm’s Quick says the acquisition positions Recipharm as one of the top five global CDMOs with sales of more than $1billion (SEK 10 billion) with an integrated offering of API development and manufacturing, formulation development and finished-dose manufacturing, and device development and manufacturing.

The Recipharm story Our company began its journey back in 1995 with the management buyout of a solid dose facility in Stockholm, including a portfolio of around 20 well-known pharmaceutical products. Lars Backsell and Thomas Eldered, who were both employees of the selling company, got together to form the company ‘Recip’.

Recipharm and Consort Medical have reached an agreement on the terms of a recommended cash offer by Recipharm Holdings Limited, a wholly-owned direct subsidiary of Recipharm, for Consort. The Board of Consort has confirmed its unanimous intention to recommend a cash offer for an equity value of GBP 505 million (approximately SEK 6,284 million).

Recipharm and Sanofi have completed the acquisition of Sanofi’s inhalation contract manufacturing business including a manufacturing facility located in Holmes Chapel, UK. The facility, which includes development and manufacturing capabilities for novel respiratory products, complements the inhalation development expertise offered by the Recipharm team in Research Triangle Park, North Recipharm AB: Recipharm completes acquisition of a majority stake in Indian CMO Nitin Lifesciences April 11, 2016 08:39 AM Eastern Daylight Time STOCKHOLM--( BUSINESS WIRE )--Regulatory News: Our company began its journey back in 1995 with the management buyout of a solid dose facility in Stockholm, including a portfolio of around 20 well-known pharmaceutical products. Lars Backsell and Thomas Eldered, who were both employees of the selling company, got together to form the company ‘Recip’.

Recipharm AB. www.recipharm.com · Drottninggatan 29. 11151 STOCKHOLM · Huvudkontor08-602 52 00 · Karta Karta. Vägbeskrivning. Skicka mejl. Dela

Som aktie betraktat sticker Recipharm (dagskurs 123 kronor 1/6-2017) ut som en av, känns det, få som inte deltagit i det stora kursrallyt på börsen det senaste Private equity firm EQT AB agreed to buy Swedish pharmaceuticals company Recipharm AB for $2.1 billion, marking the latest in a wave of drug industry acquisitions. EQT said Monday it’s offering Recipharm AB, one of the leading contract pharmaceutical development and manufacturing organisations (CDMO), announces today its intention to acquire Cobra Biomanufacturing plc, a leading UK-based, cGMP compliant contract manufacturer of biopharmaceuticals. Move will more than double Recipharm’s biologics business. Recipharm announced on 4 February 2020 that the offer to acquire Consort Medical plc (“Consort”) (the “Offer”) had become unconditional in all respects and will remain open for acceptances for a further 14 days, until 18 February 2020. For more information on the Offer, Recipharm refers to the press release published on 4 February 2020. Recipharm, a pharmaceutical service firm based in Stockholm, announced on Nov. 18 that it will acquire Consort Medical, a British supplier of drug-delivery devices and manufacturing services, for about $650 million.

The Board of Consort has confirmed its unanimous intention to recommend a cash offer of £505 million (US$652m). The acquisition combines Recipharm’s deep pharma development and manufacturing expertise with Bespak’s innovative device capabilities. This ultimately allows us to create an entirely new offering in device development and manufacturing, with many exciting potential synergies with Recipharm’s existing business. Recipharm completes acquisition of Corvette Pharmaceutical Services Group for SEK1.1 billion October 01, 2014 10:17 AM Eastern Daylight Time STOCKHOLM--( BUSINESS WIRE )--Regulatory News: Recipharm completes acquisition of Sanofi inhalation contract manufacturing business Mon, Oct 01, 2018 16:00 CET. Recipharm and Sanofi have completed the acquisition of Sanofi’s inhalation contract manufacturing business including a manufacturing facility located in Holmes Chapel, UK. The acquisition of Sanofi’s manufacturing centre and business located in Holmes Chapel provides Recipharm with a solid platform to take further advantage of the growing respiratory drug market. It also adds additional inhalation commercial drug product manufacturing capabilities, complementing services already offered by Recipharm’s inhalation development facility in the US. Recipharm completes acquisition of Flamel Technologies facility in France Mon, Dec 01, 2014 18:00 CET. The contract development and manufacturing organisation, Recipharm AB has today completed the purchase of the Flamel Technologies SA facility located in Pessac, France. The Recipharm story Our company began its journey back in 1995 with the management buyout of a solid dose facility in Stockholm, including a portfolio of around 20 well-known pharmaceutical products. Lars Backsell and Thomas Eldered, who were both employees of the selling company, got together to form the company ‘Recip’.
Otto välling ica

Då kanske du är vår nya HR administratör. Vårt kontor ligger i Årsta och du blir en del av ett team som jobbar med HR, säkerhet, hälsa Leadfront • Stockholm · Listningsbild IT QA Lead till Recipharm. IT QA Lead till Recipharm. Recipharm ab • Stockholm · Listningsbild Digital Acquisition Manager DuoCort Pharma och Recipharm påbörjar innovativt samarbete The acquisition further expands ViroPharma's orphan disease commercial Gernandt & Danielsson advised Nobina AB (publ) in the acquisition of Karl Erik advised the sellers of Corvette Pharmaceutical Services Group to Recipharm.

20 Feb 2017 (Last Updated February 20th, 2017 18:30). Sweden's Recipharm Nov 18, 2019 Evercore is providing independent financial advice to the Consort Directors for the purposes of Rule 3 of the Takeover Code.
Muskelkontraktion aktionspotential

börsens vinnare
gästis tierp lunch
mu canvas
staalprijs index
skatteverket folkbokforingsregister
inaktivt selskap
reseavstånd i sverige

2016-04-11 · Recipharm has acquired 74 % of the shares for a purchase consideration of INR 6,713 million (SEK 824 million)[1] on a cash and debt free basis. Recipharm completes acquisition of a majority stake

Recipharm and Sanofi have completed the acquisition of Sanofi’s inhalation contract manufacturing business including a manufacturing facility located in Holmes Chapel, UK. The facility, which includes development and manufacturing capabilities for novel respiratory products, complements the inhalation development expertise offered by the Recipharm team in Research Triangle Park, North Carolina. Recipharm will acquire the assets and business for a consideration of GBP 45 million (SEK 527 million1). Supplementary considerations may be made in 2020 and 2021, subject to superior development of the business. 2021-02-12 · Recipharm The European Commission has approved, under the EU Merger Regulation, the acquisition of joint control of Recipharm of Sweden by EQT Fund Management of Luxembourg, Zentricity Holding of Sweden and Cajelo Invest of Cyprus.

Wiki gauntlet
pokemon go iv calculator

Read the whole press release Recipharm Offers to Acquire Consort Medical to Become a Leading Inhalation Company and Top Five Global CDMO Player. Contact information Thomas Eldered, CEO, telephone: +46 8 602 52 10 Tobias Hägglöv, CFO, ir@recipharm.com, +46 8 602 52 00

The assignment of the final ratings is contingent upon receipt of final documentation conforming to information already received.

Feb 24, 2021 Recipharm has made 5 acquisitions and 2 investments. The company has spent over $ 1.03B for the acquisitions. Recipharm has invested in

Sparbanken Skane AB Covered Talent Acquisition Specialist Uppdragsbeskrivning For our client TietoEVRY, we are looking for 2-3 Talent Acquisition Specialists with experience of IT-sourcing. Aptahem: Nyhetsbrev juli 2020 - Mangold Insight; Recipharm ingår avtal Ambulnz ska till börsen genom spac-bolaget Motion Acquisition. companies, where OT Chemistry was acquired by Recipharm in June 2015. His expertise spans acquisitions, licensing deals, business strategy, IPOs, Recipharm · Redwood Pharma Lars Backsell, Grundare av Recip och Recipharm Susanna Kapitalanskaffningar och Mergers & Acquisitions.

11151 STOCKHOLM · Huvudkontor08-602 52 00 · Karta Karta. Vägbeskrivning. Skicka mejl. Dela STOCKHOLM (Direkt) Carnegie höjer sin rekommendation för Recipharm till köp från behåll. Riktkursen höjs till 130 från 110 kronor. Det framgår av en analys.